These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32268542)

  • 1. Thyroid Hormone Diseases and Osteoporosis.
    Delitala AP; Scuteri A; Doria C
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32268542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical thyroid dysfunction and circulating thyroid hormones are not associated with bone turnover markers or incident hip fracture in older men.
    Siru R; Alfonso H; Chubb SAP; Golledge J; Flicker L; Yeap BB
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):93-99. PubMed ID: 29655173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women.
    Morris MS
    Bone; 2007 Apr; 40(4):1128-34. PubMed ID: 17236836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of thyroid diseases on bone].
    Tsourdi E; Lademann F; Siggelkow H
    Internist (Berl); 2018 Jul; 59(7):661-667. PubMed ID: 29744522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
    Faber J; Jensen IW; Petersen L; Nygaard B; Hegedüs L; Siersbaek-Nielsen K
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):285-90. PubMed ID: 9578817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
    Appetecchia M
    Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is there a need for treatment in subclinical hypo- and hyperthyroidism?].
    Lerch M; Meier C; Staub JJ
    Ther Umsch; 1999 Jul; 56(7):369-73. PubMed ID: 10434773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Thyroid Pathology on Osteoporosis and Fracture Risk: A Review.
    Apostu D; Lucaciu O; Oltean-Dan D; Mureșan AD; Moisescu-Pop C; Maxim A; Benea H
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32156092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The skeletal consequences of thyrotoxicosis.
    Nicholls JJ; Brassill MJ; Williams GR; Bassett JH
    J Endocrinol; 2012 Jun; 213(3):209-21. PubMed ID: 22454529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women.
    van Rijn LE; Pop VJ; Williams GR
    Eur J Endocrinol; 2014 Mar; 170(3):461-8. PubMed ID: 24336745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only.
    Papi G; Pearce EN; Braverman LE; Betterle C; Roti E
    Am J Med; 2005 Apr; 118(4):349-61. PubMed ID: 15808130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism.
    Földes J; Lakatos P; Zsadányi J; Horváth C
    Eur J Endocrinol; 1997 Mar; 136(3):277-81. PubMed ID: 9100552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Subclinical thyroid disease--should we treat, should we screen for it?].
    Trbojević B
    Srp Arh Celok Lek; 2003; 131(11-12):467-73. PubMed ID: 15114790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of thyroid disorders on the bone].
    Mikosch P
    Wien Med Wochenschr; 2005 Oct; 155(19-20):444-53. PubMed ID: 16425000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.